Ron Bentsur - 23 Aug 2022 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role: Chairman & CEO, Director, 10%+ Owner
Signature: /s/ Ron Bentsur
Issuer symbol: NVCT
Transactions as of: 23 Aug 2022
Net transactions value: +$13,570
Form type: 4
Filing time: 30 Aug 2022, 07:35:34 UTC
Previous filing: 22 Aug 2022
Next filing: 06 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCT	Common Stock	Purchase	$4,500	+500	+0.02%	$9.00	3,007,909	23 Aug 2022	Direct	F1
transaction	NVCT	Common Stock	Purchase	$9,070	+1,000	+0.03%	$9.07	3,008,909	29 Aug 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 96,759 shares of restricted stock and 120,000 restricted stock units.
F2	Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.99 to $9.31. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Content

Includes 96,759 shares of restricted stock and 120,000 restricted stock units.

Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.99 to $9.31. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.